The Complete Success in Refractory Mooren’s Ulcer Treated with Infliximab


Çakmak A. İ. , Akova Y., YILDIRIM N.

Ocular Immunology and Inflammation, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Letter
  • Publication Date: 2022
  • Doi Number: 10.1080/09273948.2022.2091615
  • Journal Name: Ocular Immunology and Inflammation
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Keywords: Anti-tumor necrosis factor alpha, immunosuppresion, infliximab, Mooren's ulcer, peripheral ulcerative keratitits, PATIENT
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

© 2022 Taylor & Francis Group, LLC.Purpose: To describe the management and outcome of two extremely rare and painful cases of Mooren’s ulcer, an idiopathic peripheral autoimmune-associated ulcerative corneal disease. Methods: Case report with literature review on the management of ocular inflammation in Mooren’s ulcer. Results: A 47-year-old female and a 76-year-old female presented with progressive bilateral Mooren’s ulcer that were refractory to conventional immunosuppressive therapy. Following treatment with infliximab, an anti-tumor necrosis factor alpha, a significant improvement in disease progression was observed, with no corneal thinning or perforation at follow-ups. Conclusion: This case report highlights how infliximab can be effective in cases with Mooren’s ulcer refractory to conventional therapies.